BioSpace News Archive

Business

Santhera Slashes Workforce in Half After Phase III DMD Failure

Santhera said the restructuring will allow the company to focus on the development of vamorolone, a first-in-class dissociative steroid with a novel mode of action that it gained the rights to from ReveraGen BioPharma.

November 2, 2020
·
3 min read
·
Alex Keown
Deals

Sanofi Picks Up Kiadis and Its Immuno-Oncology Assets for $359 Million

Kiadis has three compounds in the clinic: K-NK002 in Phase II for HSCT in blood cancer; K-NK003 for relapsed or refractory acute myeloid leukemia (AML); K-NK-ID101 for COVID-19.

November 2, 2020
·
3 min read
·
Mark Terry
Deals

PerkinElmer Expands Horizons with $383 Million CRISPR Tech Acquisition

Horizon Discovery Group brings new gene editing and gene modulation tools to PerkinElmer’s expanding life sciences portfolio.

November 2, 2020
·
2 min read
·
Kate Goodwin
Drug Development

Study: CureVac’s COVID-19 Vaccine CVnCoV Produces Immune Responses in Healthy Volunteers

Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.

November 2, 2020
·
3 min read
·
Brandon May
Business

Icosavax Turns VLP Tech to COVID-19 Vaccine, with $16.5 Million in New Financing

BioSpace caught up with Icosavax CEO Adam Simpson to discuss its new vaccine candidate, IVX-411.

November 2, 2020
·
5 min read
·
Gail Dutton
Perceptive Advisors Close on $1.1 Billion Credit Fund for Life Sciences Investments

The Perceptive Advisors has completed the fundraising for its third credit fund. The fund was so enticing to investors that it hit its $1.1 billion hard caps.

November 2, 2020
·
3 min read
·
Mark Terry
Business

At Campaign Rally, Trump Hints He Could Fire Fauci Following the Election

During a Sunday campaign event in Florida, President Donald Trump appeared to hint to the crowd that following the Nov. 3 election, he would terminate the decades-long tenure of Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

November 2, 2020
·
3 min read
·
Alex Keown
Drug Development

Regeneron Hits Pause on LUMINA-1 Trial Due to Concerns with Garetosmab

Regeneron announced on Friday that it is pausing dosing of garetosmab (REGN2477), an investigational therapy, in the Phase I LUMINA-1 trial.

November 2, 2020
·
3 min read
·
Krystle Vermes
Business

Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer

Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes, has appointed Dr Suhail Nurbhai as Chief Medical Officer with immediate effect.

November 2, 2020
·
4 min read
BioMidwest

Exact Sciences to participate in November 2020 investor conferences

Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

November 2, 2020
·
6 min read